IMIBIC

IMIBIC is a health research institute founded on 24 August 2008 following an agreement between the Consejería de Salud, the Consejería de Innovación, Ciencia y Empresa of the Junta de Andalucía (the regional Department of Health, the regional Department of Innovation, Science and Business of the Andalusian Regional Government), and the University of Córdoba, signed on 29 July 2007.

IMIBIC works in collaboration with the University of Córdoba and the Reina Sofía University Hospital, a public hospital with a high level of care and strongly committed to the training of health professionals.

IMIBIC is managed by the Fundación para la Investigación Biomédica de Córdoba (FIBICO, Córdoba Foundation for Biomedical Research), founded on 27 December, 2007.

Our group falls within the research program: Cancer (Oncology and Oncohematology) focused on the study of neplastic diseases, including both solid tumors and hematologic neoplasms.

This area brings together researchers who tackle scientific problems using new technologies with significant potential for being applied to Health Sciences, including metabolomics, proteomics, epigenetics and artificial vision systems, underpinned by a cross-disciplinary ethos and supporting the various scientific programs the IMIBIC has prioritized.

The goal of the GC-22-EPIGENETICS group is to study the relevance of the DNA repair system to the maintenance and control of genetic and epigenetic information. We also propose to analyse the relationship between the demethylation of DNA and various modifications to chromatin structure.